Arcutis Biotherapeutics, Inc. (ARQT)

Market Cap	1.84B
Revenue (ttm)	263.47M
Net Income (ttm)	-93.27M
Shares Out	119.91M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,167,314
Open	15.46
Previous Close	15.52
Day's Range	15.24 - 16.12
52-Week Range	8.03 - 17.75
Beta	1.85
Analysts	Strong Buy
Price Target	19.00 (+24.02%)
Earnings Date	Aug 6, 2025

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2020
• Employees: 342
• Stock Exchange: NASDAQ
• Ticker Symbol: ARQT
• Website: https://www.arcutis.com

Financial Performance

In 2024, Arcutis Biotherapeutics's revenue was $196.54 million, an increase of 229.74% compared to the previous year's $59.61 million. Losses were -$140.04 million, -46.58% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price target is $19.0, which is an increase of 24.02% from the latest price.

Price Target

$19.0

(24.02% upside)

Analyst Consensus: Strong Buy